Temanogrel

N/A

Report date: 2022/09/15 20:00:42
NME

Base Information

Drug NameTemanogrel
Drug Alias Name特玛格雷temanogreltemanogrelumAPD-791
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor inverse agonists
TargetsSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsAcute Coronary SyndromeCREST Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesArena Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncIldong Pharmaceutical Co LtdArena Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsAcute Coronary SyndromeCREST Syndrome

Other Information

ATC CodeN/A
Related LinksKEGG